Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.

Virology - 25 Apr 2010

Ogert Robert A, Hou Yan, Ba Lei, Wojcik Lisa, Qiu Ping, Murgolo Nicholas, Duca Jose, Dunkle Lisa M, Ralston Robert, Howe John A

Abstract excerpt

The HIV-1 CCR5 co-receptor is a member of the chemokine receptor family of G-protein coupled receptors; for which a number of small molecule antagonists, such as vicriviroc (VCV), have been developed to inhibit HIV-1 R5-tropic replication. In this study, we analyzed an HIV-1 subtype D envelope ge...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCR5 Receptor Antagonists
Share to HIV Antibodies
Share to HIV Envelope Protein gp120

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Host-Pathogen Interactions

Share to Piperazines

Share to Pyrimidines

Share to Receptors, CCR5

Share to Virus Internalization

Source

Identifiers

PMID: 20172579
DOI: 10.1016/j.virol.2010.01.037

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20172579-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.PMID 20172579Read ↗

Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist VicrivirocSemantic proximity Read ↗

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.Semantic proximity Read ↗

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.Semantic proximity Read ↗

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected SubjectSemantic proximity Read ↗

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and VicrivirocSemantic proximity Read ↗

HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage TropismSemantic proximity Read ↗

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.Semantic proximity Read ↗

Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Semantic proximity Read ↗

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitorsSemantic proximity Read ↗

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 CoreceptorSemantic proximity Read ↗

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.Semantic proximity Read ↗

Characterization of Emergent HIV Resistance in Treatment‐Naive Subjects Enrolled in a Vicriviroc Phase 2 TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.